Drug pric­ing dis­rup­tor EQRx makes the big leagues with $1.8B SPAC deal and a new CEO at the helm

EQRx, a would-be drug pric­ing dis­rup­tor that has emerged as an in­vestor dar­ling, has every­thing but an ap­proval to show in its fight against fi­nan­cial tox­i­c­i­ty in bio­phar­ma. With the home­stretch clos­ing in, the team is now ready for its close-up.

EQRx will re­verse merge with the CM Life Sci­ences III SPAC, kick­start­ed by biotech blue chip­per Cas­din Cap­i­tal and Corvex Man­age­ment, and go pub­lic as part of a deal that will in­fuse around $1.8 bil­lion in­to the drug pric­ing dis­rup­tor’s bank ac­count, the part­ners said Fri­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER